|Bid||9.72 x 1100|
|Ask||10.01 x 2200|
|Day's Range||9.69 - 10.10|
|52 Week Range||4.01 - 14.04|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The idea was simple, if you came in to look at the paintings of undiscovered artists that we had found, you could browse through the rooms with a plastic cup of a decent bottle of chardonnay. just sold, because cheap spirits just don't sell well anymore.
For the fourth quarter, T-Mobile (TMUS) is likely to report higher year-over-year revenues driven by customer growth on the back of coverage expansion and network performance.
For the fourth quarter, GoPro (GPRO) is likely to report higher year-over-year revenues driven by increasing market traction of HERO7 Black.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...
The third quarter for the initial public offering (IPO) market is usually lighter. During the latest quarter, there were 49 IPOs and the average return was a sizzling 32.55%. Before the cannabis producer Tilray (NASDAQ:TLRY) came public, I wrote the following for InvestorPlace.com: “And yes, Tilray IPO does offer an easy way for investors to play this trend.
The development-stage biotechnology company Constellation Pharmaceuticals, Inc. (NASDAQ: CNST ) uses protein interaction to treat myelofibrosis, in addition to addressing prostate cancer and other tumors. ...